Savings from switching to bevacizumab for retinal disorders are underestimatedBMJ 2014; 349 doi: https://doi.org/10.1136/bmj.g7522 (Published 10 December 2014) Cite this as: BMJ 2014;349:g7522
- Frank Ahfat, consultant ophthalmic surgeon1
- 1Maidstone and Tunbridge Wells NHS Trust, Maidstone ME16 9QQ, UK
Lotery and MacEwen report that a switch from ranibizumab to bevacizumab for macular degeneration and other retinal disorders could save the NHS £102m (€129m; $160m) annually.1 In 2012, the IVAN study group suggested annual savings of £84m from such a switch.2 This second …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial